那米罗汀 | 101506-83-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 那米罗汀
• 英文名称: Namirotene
• 英文别名: 4-[(E)-2-(5-propan-2-ylthiophen-2-yl)prop-1-enyl]benzoic acid
• CAS: 101506-83-6
• 化学式: C₁₇H₁₈O₂S
• 分子量: 286.4
• InChiKey: GDDUESKGWJTHLR-ZRDIBKRKSA-N

物化性质

• 沸点：
  431.1±45.0 °C(Predicted)
• 密度：
  1.170±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  以40的产率得到那米罗汀
  参考文献：
  名称：

  New derivatives of 4-vinyl benzoic acid, process for their preparation

  摘要：

  本发明涉及公式##STR1##的化合物。这些化合物可用于治疗痤疮、银屑病、角化病变、某些癌症形式以及作为愈合剂，特别是在眼科领域。

  公开号：

  US04929635A1

文献信息

• Dendrimers as molecular translocators
  申请人：Goodman Murray

  公开号：US20060216265A1

  公开（公告）日：2006-09-28

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  转运分子包括一种树枝状聚合物和一种生物活性分子。这些转运分子的树枝状聚合物包括至少一个胍基团、至少一个质子化的胍基团、至少一个保护的胍基团、至少一个酰胺基团、至少一个质子化的酰胺基团、至少一个保护的酰胺基团、至少一个脲基团、至少一个质子化的脲基团、至少一个保护的脲基团、至少一个硫脲基团、至少一个质子化的硫脲基团，或至少一个保护的硫脲基团。生物活性分子与树枝状聚合物结合。一种增加药物生物利用度的方法包括将药物与本发明的树枝状聚合物结合。
• Therapeutic methods employing disulfide derivatives of dithiocarbamates and compositions useful therefor
  申请人：Medinox, Inc.

  公开号：US20030181495A1

  公开（公告）日：2003-09-25

  The present invention provides novel combinations of dithiocarbamate disulfide dimers with other active agents. In one method, the disulfide derivative of a dithiocarbamate is coadministered with a thiazolidinedione for the treatment of diabetes. In another embodiment, In another embodiment, invention combinations further comprise additional active agents such as, for example, metformin, insulin, sulfonylureas, and the like. In another embodiment, the present invention relates to compositions and formulations useful in such therapeutic methods.

  本发明提供了二硫代氨基甲酸盐二硫化二聚体与其他活性药剂的新组合。在一种方法中，二硫代氨基甲酸盐的二硫化衍生物与噻唑烷二酮联合用于治疗糖尿病。在另一实施例中，该发明的组合进一步包括额外的活性药剂，例如二甲双胍、胰岛素、磺酰脲类药物等。在另一实施例中，本发明涉及用于这种治疗方法的组合物和配方。
• Pharmaceutical preparation comprising an active dispersed on a matrix
  申请人：——

  公开号：US20040058896A1

  公开（公告）日：2004-03-25

  The present invention relates to the field of pharmaceutical technology and describes a novel advantageous preparation for an active ingredient. The novel preparation is suitable for producing a large number of pharmaceutical dosage forms. In the new preparation an active ingredient is present essentially uniformly dispersed in an excipient matrix composed of one or more excipients selected from the group of fatty alcohol, triglyceride, partial glyceride and fatty acid ester.

  本发明涉及制药技术领域，描述了一种新的有利的活性成分制备方法。这种新的制备方法适用于生产大量的药物剂型。在这种新的制备方法中，活性成分基本上均匀地分散在由脂肪醇、甘油三酯、部分甘油酯和脂肪酸酯等多种赋形剂中选择的一种或多种赋形剂组成的赋形剂基质中。
• New derivatives of 4-vinyl benzoic acid, process for their preparation
  申请人：Laboratoires Chauvin-Blache

  公开号：US04929635A1

  公开（公告）日：1990-05-29

  The invention relates to compounds of the formula ##STR1## These compounds may be used in therapeutics for the treatment of acne, psoriasis, disorders of keratinization, in certain forms of cancer and as healing agents, particularly in the ocular field.

  本发明涉及公式##STR1##的化合物。这些化合物可用于治疗痤疮、银屑病、角化病变、某些癌症形式以及作为愈合剂，特别是在眼科领域。
• Dendrimers as Molecular Translocators
  申请人：Goodman Murray

  公开号：US20080221020A1

  公开（公告）日：2008-09-11

  Transport molecules include a dendrimer and a biologically active molecule. The dendrimer of such transport molecules includes at least one guanidine group, at least one protonated guanidine group, at least one protected guanidine group, at least one amidine group, at least one protonated amidine group, at least one protected amidine group, at least one ureido group, at least one protonated ureido group, at least one protected ureido group, at least one thioureido group, at least one protonated thioureido group, or at least one protected thioureido group. The biologically active molecule is bonded to the dendrimer. A method of increasing the bioavailability of a drug includes bonding the drug to a dendrimer of the invention.

  运输分子包括一个树状分子和一个生物活性分子。这种运输分子的树状分子包括至少一个鸟氨酸基团，至少一个质子化的鸟氨酸基团，至少一个保护的鸟氨酸基团，至少一个酰胺基团，至少一个质子化的酰胺基团，至少一个保护的酰胺基团，至少一个尿素基团，至少一个质子化的尿素基团，至少一个保护的尿素基团，至少一个硫脲基团，至少一个质子化的硫脲基团，或者至少一个保护的硫脲基团。生物活性分子与树状分子结合。一种增加药物生物利用度的方法包括将药物与本发明的树状分子结合。